Baird Reiterates an 'Outperform' on Human Genome Sciences (HGSI); 2 Survey on Benlysta Launch: Signs of Armageddon Nowhere To Be Found

Baird reiterates an 'Outperform' on Human Genome Sciences (NASDAQ: HGSI) price target of $27.00.

Baird analyst says, "With the backdrop of significant investor angst over Benlysta's launch prospects, we highlight herein fresh survey data (fielded early July) indicating favorability ratings, use trends and reimbursement experiences actually improved measurably from the last survey (May). While we recently lowered our estimates to prove a point on valuation, this feedback increases our confidence that our and consensus estimates may ultimately prove conservative. Remain aggressive buyers for a rebound back into the high $20s."

For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.

Shares of Human Genome Sciences closed at $15.81 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
• Northland Upgrades CIENA (CIEN) to Outperform
• UBS Downgrades Cellnex Telecom (CLNX:SM) (CLNXF) to Neutral